Oncopeptides AB (STU:OND) Total Operating Expense : €27.94 Mil (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Oncopeptides AB Total Operating Expense?

Oncopeptides AB's Total Operating Expense for the three months ended in Mar. 2025 was €6.68 Mil. Oncopeptides AB's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was €27.94 Mil.

Oncopeptides AB Total Operating Expense Historical Data

The historical data trend for Oncopeptides AB's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Total Operating Expense Chart

Oncopeptides AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Operating Expense

Get a 7-Day Free Trial

156.41

144.69

32.79

26.00

27.25

Oncopeptides AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Operating Expense	Get a 7-Day Free Trial															6.23	7.13	6.08	8.04	6.68

Oncopeptides AB Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.

Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €27.94 Mil.

Oncopeptides AB Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (STU:OND) » Definitions » Total Operating Expense

Comparable Companies

Traded in Other Exchanges

ONCO:Sweden 0RN4:UK

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.